Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the health-check domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /www/vativorx_714/public/wp-includes/functions.php on line 6121
The Missing Piece: How Self-Insured Employers Can Capture Medical Rebates Overlooked by PBMs - VativoRx

Call Us: 888-488-5750

The Missing Piece: How Self-Insured Employers Can Capture Medical Rebates Overlooked by PBMs

As healthcare costs continue to climb, self-insured employers are under pressure to find new ways to manage spending without compromising care. While many have implemented pharmacy benefit management (PBM) solutions, a significant opportunity often goes unnoticed: rebates tied to provider-administered medications billed under the medical benefit.

Why Medical Rebates Are Overlooked

PBMs typically focus on pharmacy claims—retail prescriptions dispensed at the pharmacy counter. However they often don’t capture rebates for medications administered by providers in outpatient clinics, infusion centers, or hospitals. These high-cost medications—like IVIG, oncology therapies, and other specialty injectables—are billed under the medical benefit, not the pharmacy benefit.

That’s where VativoRx steps in.

The Rebate Opportunity for Self-Insured Employers

Self-insured employers are responsible for paying their employees’ healthcare claims directly. That means every unclaimed rebate is real money left on the table. As specialty drugs now make up over 50% of total drug spend, overlooking medical rebate opportunities creates a growing financial gap.

Rebates on provider-administered drugs can offer substantial returns—but they require expertise, data validation, and compliance know-how that most PBMs and employers don’t have in-house.

How VativoRx Fills the Gap

VativoRx partners with self-insured employers to identify and recover rebates on the medical side—working alongside their existing PBM or benefit structure, not replacing it.

We provide:

Data segmentation and claims validation to identify eligible medical claims

Compliance oversight and secure submission to manufacturers or aggregators

Therapeutic class-level insights, including areas like Oncology, IVIG, Respiratory, and more

Audit-ready reporting to ensure transparency

All without requiring changes to formularies, billing systems, or provider contracts.

The Bottom Line

Healthcare costs are complex, but the opportunities for savings don’t have to be. By capturing rebates PBMs often overlook, self-insured employers can unlock meaningful financial value while supporting better care delivery.

VativoRx doesn’t replace your PBM—we enhance what they don’t cover. And in today’s cost environment, that missing piece matters.

Want to explore what’s possible? Contact Us!

VativoRx Joins MHA: A New Chapter Begins

The world of healthcare is dynamic, continuously evolving with new challenges and opportunities. At VativoRx, we’ve always believed in the power of innovation, collaboration, and dedication to ensure that we provide the best rebate management solutions in the industry. Today, we’re thrilled to announce our latest milestone: VativoRx is now an official associate member of the Michigan Health & Hospital Association (MHA)!

Read More »

Unveiling the Future: Navigating the Evolving Landscape of 340B Rebates.

The 340B Drug Pricing Program, established in 1992, has been a crucial component of the healthcare system, dedicated to assisting eligible healthcare organizations in serving vulnerable patient populations by granting them access to discounted drugs. At the heart of this program are the 340B rebates, which enable qualifying entities such as safety-net hospitals, community health centers, and other eligible providers to acquire medications at significantly reduced prices.

Read More »
Martin Shields / Alamy Stock Photo

Humira – The End of an Era

In January 2023, the first biosimilar version of Humira, which is a widely used injectable drug for inflammatory diseases, was approved, marking the end of AbbVie’s two-decade market exclusivity. Humira is used to treat conditions like rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis, and it works by targeting certain proteins in the immune system.

Read More »